Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: A randomised trial

International Journal of Cardiology

Volumn 115, Issue 1, 2007, Pages 57-62

  Carbonell, Nieves ^a   Blasco, Marisa ^a   Sanjuán, Rafael ^a   Pérez Sancho, Esther ^a   Sanchis, Juan ^a   Insa, Luis ^a   Bodí, Vicente ^a   Núñez, Julio ^a   García Ramón, Rafael ^a   Miguel, Alfonso ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Contrast induced nephropathy; Coronary angiography; N Acetylcysteine

Indexed keywords

ACETYLCYSTEINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IOPROMIDE; NITRITE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SODIUM CHLORIDE;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYDRATION; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY FUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SIDE EFFECT; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

ACETYLCYSTEINE; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTECTIVE AGENTS;

EID: 33845233344     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.04.023     Document Type: Article

References (32)

1. Dzavik V. New frontiers and unresolved controversies in percutaneous coronary intervention. Am J Cardiol 81 (2003) 27A-33A
2. Rihal C.S., Textor S.C., Grill D.E., et al. Incidence and prognostic importance of acute renal failure after percutaneos coronary intervention. Circulation 105 (2002) 2259-2264
3. Manske C.L., Sprafka J.M., Strony J.T., and Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 89 (1990) 615-620
4. Gruberg L., Mintz G., Mehran R., et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 36 (2000) 1542-1548
5. Mc Cullough P.A., Wolyn R., Rocher L.L., Levin R.N., and O'Neill W.W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103 (1997) 368-375
6. Bartholomewm B.A., Harjai K.L., Dukkipati S., et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 93 (2004) 1515-1519
7. Tepel M., Van der Giet M., Schwarzfeld C., Laufer U., Liermann D., and Zidek W. Prevention of radiographic-contrast-induced reductions in renal function by acetylcysteine. N Engl J Med 343 (2000) 180-184
8. Diaz-Sandoval L.J., Kosowsky B.D., and Losordo D.W. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 89 (2002) 356-358
9. Shyu K.J., Cheng J.J., and Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 40 (2002) 1383-1388
10. Kay J., Chow W.H., Chan T.M., et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 289 (2003) 553-558
11. MacNeill B.D., Harding S.A., Bazari H., et al. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 60 (2003) 458-461
12. Baker C.S.R., Wragg A., Kmar S., De Palma R., Baker L.R.I., and Knight C.J. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 41 (2003) 2114-2118
13. Briguori C., Colombo A., Violante A., et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 25 (2004) 206-211
14. Briguori C., Manganelli F., Scarpato P., et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40 (2002) 298-303
15. Allaqaband S., Tumuluri R., Malik A.M., et al. Prospective randomized study of N-acetylcysteine, fenoldopan, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 57 (2002) 279-283
16. Durham D.J., Caputo C., Dokko J., et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 62 (2002) 2202-2207
17. Oldemeyer J., Biddle P., Wurdeman R., Mooss A., Cichowski E., and Hilleman D. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 146 (2003) e23
18. Goldenberg I., Shechter M., Matetzky S., et al. Oral acetylcysteine as an adjunt to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. Eur Heart J 25 (2004) 212-218
19. Birck R., Krzossok S., Markowetz F., Schnulle P., van der Woude F.J., and Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 362 (2003) 598-603
20. Pannu N., Manns B., Lee H., and Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 65 (2004) 1366-1374
21. Webb J., Pate G., Humphries K., et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterisation: lack of effect. Am Heart J 148 (2004) 422-429
22. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
23. Cigarroa R.G., Lange R.A., Williams R.H., and Hillis L.D. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 86 (1989) 649-652
24. Freeman R.V., O'Donnell M., Share D., et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 90 (2002) 1068-1073
25. Noto T.J., Johnson L.E., Krone R., et al. Cardiac catheterisation 1990: a report of the registry of the Society for Cardiac Angiography and Interventions. Catheter Cardiovasc Diagn 24 (1991) 75-83
26. Chalmers N., and Jackson R.W. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 72 (1999) 701-703
27. Aspelin P., Aubry P., Fransson S.G., Strasser R., Willenbrock R., and Berg K.J. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348 (2003) 491-499
28. Borgstrom L., Kagedal B., and Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 31 (1986) 217-222
29. Jones A.L., Jarvie D.R., Simpson D., Hayes P.C., and Prescott L.F. Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. Aliment Pharmacol Ther 11 4 (1997) 787-791
30. Olsson B., Johansson M., Gabrielsson J., and Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 4 (1988) 77-82
31. Hoffmann U., Fischereder M., Kruger B., Drobnik W., and Kramer B. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15 (2004) 407-410
32. Shalansky S.J., Pate G.E., Levin A., and Webb J.G. N-Acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration. Heart 91 (2005) 997-999